Richard F Little (R F Little)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 24

Top Topics

Acute Myeloid Leukemia

Multiple Myeloma

Prognostic Factors

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth Paietta, Susan M O'Brien, Jacqueline Claudia Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Zhang, Paul M Barr, Amanda F Cashen, Anthony R Mato, Avina K Singh, Michael Mullane, Richard F Little, Harry P Erba, Richard M Stone, Mark R Litzow, Martin S Tallman, Neil E Kay
Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912. Blood advances (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina M Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Naomi Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood 143 (16) (2024)
Jennifer A Woyach, Gabriela E Perez Burbano, Amy S Ruppert, Cecelia R Miller, Nyla A Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L Bartlett, Danielle M Brander, Paul M Barr, Kerry A Rogers, Sameer A Parikh, Deborah M Stephens, Jennifer R Brown, Gerard Lozanski, James S Blachly, Sreenivasa Nattam, Richard A Larson, Harry P Erba, Mark R Litzow, Selina M Luger, Carolyn Owen, Charles Kuzma, Jeremy S Abramson, Richard F Little, Shira Naomi Dinner, Richard M Stone, Geoffrey L Uy, Wendy Stock, Sumithra J Mandrekar, John C Byrd
Long-term Follow-up from A041202 Shows Continued Efficacy of Ibrutinib Regimens for Older Adults with CLL. Blood (2024)
Mitchell Reed Smith, Opeyemi A Jagede, Peter Martin, Brian Till, Samir Parekh, David T Yang, Eric D Hsi, Thomas E Witzig, Sandeep S Dave, David W Scott, Curtis A Hanson, Lale Kostakoglu, Nizar N Abdel Samad, Carla Casulo, Nancy L Bartlett, Paolo F Caimi, Tareq Al Baghdadi, Kristie Blum, Mark Romer, David J Inwards, Rachel Lerner, Lynne I Wagner, Richard F Little, Jonathan W Friedberg, John P Leonard, Brad S Kahl
Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma. Blood (2024)
Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian L Link, Bayard L Powell, Christopher Melani, Andrea Nicole Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S Kahl, Richard F Little, Nancy L Bartlett, Ariela Noy, Wyndham H Wilson, Mark J Roschewski
Prognostic Factors for Adult Burkitt Lymphoma Patients Treated with Dose-Adjusted EPOCH-R. Blood advances (2023)
Peter J O'Dwyer, Robert J Gray, Keith T Flaherty, Helen X Chen, Shuli Li, Victoria Wang, Lisa Meier McShane, David R Patton, James V Tricoli, P Mickey Williams, A John Iafrate, Jeffrey Sklar, Edith P Mitchell, Naoko Takebe, David J Sims, Brent Coffey, Tony Fu, Mark Routbort, Lawrence V Rubinstein, Richard F Little, Carlos L Arteaga, Donna Marinucci, Stanley R Hamilton, Barbara A Conley, Lyndsay N Harris, James H Doroshow
The NCI-MATCH trial: lessons for precision oncology. Nature medicine (2023)
Lyndsay N Harris, Charles David Blanke, Harry P Erba, James M Ford, Robert C Gray, Michael L LeBlanc, Siwen Hu-Lieskovan, Mark R Litzow, Selina M Luger, Funda Meric-Bernstam, Peter J O'Dwyer, Megan K D Othus, Katerina Politi, Lois E Shepherd, Carmen J Allegra, Helen X Chen, Susan Percy Ivy, Larissa A Korde, Richard F Little, Lisa Meier McShane, Jeffrey A Moscow, David R Patton, Magdalena Thurin, Laura M Yee, James H Doroshow
The New NCI Precision Medicine Trials. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Lakshmi Rajdev, Chia-Ching Jackie Wang, Himanshu N Joshi, Shelly Lensing, Jeannette Lee, Juan Carlos Ramos, Robert Baiocchi, Lee Ratner, Paul G Rubinstein, Richard Ambinder, David Henry, Howard Streicher, Richard F Little, Elizabeth Chiao, Dirk P Dittmer, Mark H Einstein, Ethel Cesarman, Ronald Mitsuyasu, Joseph A Sparano, null null
Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Cancer (2023)
Mirinal S Patnaik, Amer M Zeidan, Eric Padron, Uwe Platzbecker, David A Sallman, Amy E DeZern, Rafael Bejar, Mikkael A Sekeres, Justin Taylor, Richard F Little, Jan P Bewersdorf, Tae Kon Kim, Nina Kim, Christopher S Hourigan, Matteo G Dela Porta, Maximilian Stahl, David Steensma, Mina L Xu, Olatoyosi Odenike, Hetty E Carraway, Pierre Fenaux, Aziz Nazha, Rami S Komrokji, Sanam Loghavi, Zhuoer Xie, Robert P Hasserjian, Michael R Savona, John M Bennett
Differences in classification schemata for myelodysplastic/myeloproliferative overlap neoplasms. Leukemia 36 (12) (2022)
Shaji K Kumar, Lawrence Baizer, Natalie S Callander, Sergio A Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul Gerard Richardson, Elena I Schwartz, Anthony Reiman, Suzanne Lentzch, Philip L McCarthy, Sundar Jagannath, Andrew J Yee, Richard F Little, Noopur S Raje
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood cancer journal 12 (6) (2022)
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan M O'Brien, Jacqueline Barrientos, Diane F Jelinek, Esteban Braggio, Jose F Leis, Cong Christine Zhang, Steven E Coutre, Paul M Barr, Amanda F Cashen, Anthony R Mato, Avina K Singh, Michael P Mullane, Richard F Little, Harry P Erba, Richard M Stone, Mark R Litzow, Martin Tallman, Neil E Kay
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood 140 (2) (2022)
Andrea M Denicoff, Susan Percy Ivy, Tami T Tamashiro, Jinxiu Zhao, Katherine H Worthington, Margaret M Mooney, Richard F Little
Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials. Journal of the National Cancer Institute 114 (11) (2022)
Amer M Zeidan, Jan Philipp Bewersdorf, Rena Buckstein, Mikkael A Sekeres, David P Steensma, Uwe Platzbecker, Sanam Loghavi, Jacqueline Boultwood, Rafael Bejar, John M Bennett, Uma Borate, Andrew M Brunner, Hetty E Carraway, Jane E Churpek, Naval G Daver, Matteo Della Porta, Amy E DeZern, Fabio Efficace, Pierre Fenaux, Maria E Figueroa, Peter Greenberg, Elizabeth A Griffiths, Stephanie Halene, Robert P Hasserjian, Christopher S Hourigan, Nina Kim, Tae Kon Kim, Rami S Komrokji, Vijay Kutchroo, Alan F List, Richard F Little, Ravindra Majeti, Aziz Nazha, Stephen D Nimer, Olatoyosi Odenike, Eric Padron, Mirinal S Patnaik, Gail J Roboz, David A Sallman, Guillermo F Sanz, Maximilian Stahl, Daniel T Starczynowski, Justin Taylor, Zhuoer Xie, Mina L Xu, Michael R Savona, Andrew H Wei, Omar Abdel-Wahab, Valeria Santini
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. Leukemia 36 (12) (2022)
Nicole Gormley, Lola A Fashoyin-Aje, Trevan Locke, Joseph M Unger, Richard F Little, Ajay Nooka, Khalid Mezzi, Mihaela Popa-McKiver, Rachel Kobos, Yelak Biru, Tiffany H Williams, Kenneth C Anderson
Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood cancer discovery 2 (2) (2022)
Maximilian Stahl, Omar Abdel-Wahab, Andrew H Wei, Michael R Savona, Mina L Xu, Zhuoer Xie, Justin Taylor, Daniel T Starczynowski, Guillermo F Sanz, David A Sallman, Valeria Santini, Gail J Roboz, Mirinal S Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D Nimer, Ravindra Majeti, Richard F Little, Steven D Gore, Alan F List, Vijay Kuchroo, Rami S Komrokji, Tae Kon Kim, Nina Kim, Christopher S Hourigan, Robert P Hasserjian, Stephanie Halene, Elizabeth A Griffiths, Peter L Greenberg, Maria E Figueroa, Pierre Fenaux, Fabio Efficace, Amy E DeZern, Matteo G Della Porta, Naval G Daver, Jane E Churpek, Hetty E Carraway, Andrew M Brunner, Uma Borate, John M Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P Steensma, Mikkael A Sekeres, Rena J Buckstein, Amer M Zeidan
An agenda to advance research in MDS: A TOP 10 Priority List from the first international workshop in MDS (iwMDS). Blood advances (2022)
Amy S Ruppert, Allison M Booth, Wei Ding, Nancy L Bartlett, Danielle M Brander, Steven Coutre, Jennifer R Brown, Sreenivasa Nattam, Richard A Larson, Harry Erba, Mark R Litzow, Carolyn Owen, Charles S Kuzma, Jeremy S Abramson, Richard F Little, Scott E Smith, Richard M Stone, John C Byrd, Sumithra J Mandrekar, Jennifer A Woyach
Adverse event burden in older patients with CLL receiving bendamustine plus rituximab or ibrutinib regimens: Alliance A041202. Leukemia 35 (10) (2021)
Grzegorz S Nowakowski, Fangxin Hong, David W Scott, William R Macon, Rebecca L King, Thomas M Habermann, Nina Wagner-Johnston, Carla Casulo, James L Wade, Gauri G Nagargoje, C M Reynolds, Jonathon B Cohen, Nadia Khan, Jennifer Effie Amengual, Kristy L Richards, Richard F Little, John P Leonard, Jonathan W Friedberg, Lale Kostakoglu, Brad S Kahl, Thomas E Witzig
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (12) (2021)
Richard F Little
Tearing down the false walls to HIV cancer care. Cancer 125 (10) (2019)
Richard F Little, Howard Streicher
Checking up on checkpoint inhibitors. Blood 130 (2) (2018)
Richard F Little, Lisa Meier McShane
Measure for measure: minimal residual disease in CLL. Blood 128 (24) (2018)
Roland Bruno Walter, Laura C Michaelis, Megan Othus, Geoffrey L Uy, Jerald P Radich, Richard F Little, Sandi Hita, Lalit Saini, James M Foran, Aaron T Gerds, Heidi D Klepin, Annette E Hay, Sarit Assouline, Jeffrey E Lancet, Stephen Couban, Mark R Litzow, Richard M Stone, Harry P Erba
Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia. American journal of hematology 93 (2) (2017)